JP2005530484A5 - - Google Patents

Download PDF

Info

Publication number
JP2005530484A5
JP2005530484A5 JP2003565508A JP2003565508A JP2005530484A5 JP 2005530484 A5 JP2005530484 A5 JP 2005530484A5 JP 2003565508 A JP2003565508 A JP 2003565508A JP 2003565508 A JP2003565508 A JP 2003565508A JP 2005530484 A5 JP2005530484 A5 JP 2005530484A5
Authority
JP
Japan
Prior art keywords
fusion protein
angiogenesis
albumin fusion
albumin
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003565508A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530484A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2003/000433 external-priority patent/WO2003066085A1/en
Publication of JP2005530484A publication Critical patent/JP2005530484A/ja
Publication of JP2005530484A5 publication Critical patent/JP2005530484A5/ja
Pending legal-status Critical Current

Links

JP2003565508A 2002-02-07 2003-02-07 アルブミン融合抗血管形成ペプチド Pending JP2005530484A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35554702P 2002-02-07 2002-02-07
PCT/IB2003/000433 WO2003066085A1 (en) 2002-02-07 2003-02-07 Albumin-fused anti-angiogenesis peptides

Publications (2)

Publication Number Publication Date
JP2005530484A JP2005530484A (ja) 2005-10-13
JP2005530484A5 true JP2005530484A5 (https=) 2005-12-22

Family

ID=27734531

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2003566175A Pending JP2005538932A (ja) 2002-02-07 2003-02-07 アルブミン融合クニッツドメインペプチド
JP2003565501A Pending JP2005516607A (ja) 2002-02-07 2003-02-07 Hiv阻害タンパク質
JP2003565508A Pending JP2005530484A (ja) 2002-02-07 2003-02-07 アルブミン融合抗血管形成ペプチド
JP2009239593A Pending JP2010046076A (ja) 2002-02-07 2009-10-16 アルブミン融合クニッツドメインペプチド

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2003566175A Pending JP2005538932A (ja) 2002-02-07 2003-02-07 アルブミン融合クニッツドメインペプチド
JP2003565501A Pending JP2005516607A (ja) 2002-02-07 2003-02-07 Hiv阻害タンパク質

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009239593A Pending JP2010046076A (ja) 2002-02-07 2009-10-16 アルブミン融合クニッツドメインペプチド

Country Status (10)

Country Link
US (4) US20060122374A1 (https=)
EP (4) EP1471928A1 (https=)
JP (4) JP2005538932A (https=)
KR (4) KR20040089608A (https=)
CN (3) CN1642567A (https=)
AU (5) AU2003244515A1 (https=)
CA (3) CA2485064A1 (https=)
NZ (3) NZ534492A (https=)
WO (3) WO2003066824A2 (https=)
ZA (3) ZA200406124B (https=)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE277081T1 (de) 1994-01-11 2004-10-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
WO2005003296A2 (en) * 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
ES2348230T3 (es) * 2002-06-07 2010-12-01 Dyax Corp. Prevención y reducción de la isquemia.
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
GB0217033D0 (en) * 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
EP2386310B1 (en) * 2002-08-28 2018-11-07 Dyax Corp. Methods for preserving organs and tissues
WO2004056852A2 (en) 2002-12-19 2004-07-08 Nektar Therapeutics Al, Corp. Cyanovirin variant-polymer conjugates
US6989369B2 (en) 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
DE602004015142D1 (de) * 2003-08-29 2008-08-28 Childrens Medical Center Antiangiogene peptide zur behandlung oder vorbeugung von endometriose
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
US9057061B2 (en) 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique
WO2006067511A1 (en) 2004-12-23 2006-06-29 Novozymes Delta Limited Gene expression technique
WO2005063282A1 (en) * 2003-12-23 2005-07-14 Centocor, Inc. Anti-retroviral agents, compositions, methods and uses
TW200607523A (en) 2004-06-01 2006-03-01 Domantis Ltd Drug compositions, fusions and conjugates
AU2011218732B2 (en) * 2004-09-27 2013-07-04 Takeda Pharmaceutical Company Limited Kallikrein Inhibitors and Uses Thereof
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
ES2325344B1 (es) * 2004-11-02 2010-06-09 Univ Madrid Autonoma Inhibidores de angiogenesis multifuncionales y multivalentes.
EP1835926A4 (en) * 2004-11-22 2009-04-01 Dyax Corp PLASMINE-INHIBITING THERAPIES
PL1981519T3 (pl) * 2005-12-29 2018-07-31 Dyax Corp. Hamowanie proteaz
CN100475270C (zh) * 2006-01-20 2009-04-08 清华大学 一种治疗肿瘤的药物及其应用
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007104541A2 (en) 2006-03-16 2007-09-20 Dyax Corp. Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders
EP2450368A1 (en) 2007-01-30 2012-05-09 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
CL2008002092A1 (es) * 2007-07-20 2009-05-29 Hoffmann La Roche Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
WO2009019314A1 (en) 2007-08-08 2009-02-12 Novozymes A/S Transferrin variants and conjugates
WO2009026539A1 (en) * 2007-08-23 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US9025330B2 (en) 2007-09-30 2015-05-05 Alcatel Lucent Recirculating gas rack cooling architecture
EP2353010B1 (en) 2008-10-28 2015-07-08 Uladzimir A. Murauski Methods for detection of toxemia
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
DK2427486T3 (en) 2009-05-07 2015-05-26 Novozymes Biopharma Dk As A process for purifying albumin
EP2493921B1 (en) 2009-10-30 2018-09-26 Albumedix Ltd Albumin variants
SMT201800552T1 (it) 2010-01-06 2018-11-09 Dyax Corp Proteine che legano la callicreina plasmatica
CN101875693B (zh) * 2010-01-22 2012-07-18 成都正能生物技术有限责任公司 具备抗血管生成活性的白蛋白变异体及其制备方法
EP2556087A1 (en) * 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
MX2013002556A (es) * 2010-09-14 2013-05-28 Hoffmann La Roche Polipeptido de fusion de dedo de serpina.
CN102453097A (zh) * 2010-10-27 2012-05-16 上海科新生物技术股份有限公司 抑制血管新生的融合蛋白vf及药物组合物和应用
US20130225496A1 (en) 2010-11-01 2013-08-29 Novozymes Biopharma Dk A/S Albumin Variants
KR102320178B1 (ko) 2011-01-06 2021-11-02 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
CA2830660A1 (en) 2011-05-05 2012-11-08 Novozymes Biopharma Dk A/S Albumin variants
CN110105453A (zh) * 2011-08-17 2019-08-09 科罗拉多大学董事会法人团体 运铁蛋白-肿瘤抑素融合蛋白质及其生成和使用方法
CN102532326B (zh) * 2011-11-18 2017-06-09 南京大学 一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
US9528992B2 (en) 2012-02-20 2016-12-27 Uladzimir A. Murauski Methods and kits for detection of active malignancy
DK2825556T3 (en) 2012-03-16 2018-04-16 Albumedix As albumin Variants
EP2890389A1 (en) * 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
MX2015005363A (es) 2012-11-08 2015-11-06 Novozymes Biopharma Dk As Variantes de albumina.
US10690670B2 (en) 2013-01-20 2020-06-23 Dyax Corp. Assays for determining levels of plasma protease C1 inhibitor
US20160033523A1 (en) 2013-02-16 2016-02-04 Novozymes Biopharma Dk A/S Pharmacokinetic animal model
WO2014182684A2 (en) * 2013-05-06 2014-11-13 Cell Machines, Inc. Methods and compositions related to large scale production of proteins
CN103333255A (zh) * 2013-06-28 2013-10-02 复旦大学 一种长效hiv‐1膜融合抑制剂
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
DE102014112212A1 (de) 2014-08-26 2016-03-03 Akesion Gmbh Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen
CN105440138A (zh) * 2014-09-30 2016-03-30 复旦大学 一种长效内皮抑素融合蛋白的制备方法和用途
WO2016196233A1 (en) * 2015-05-30 2016-12-08 Genomatica, Inc. Vinylisomerase-dehydratases, alkenol dehydratases, linalool dehydratases and/ crotyl alcohol dehydratases and methods for making and using them
CN104926946B (zh) * 2015-07-13 2021-09-17 中国科学院广州生物医药与健康研究院 具有延长体内半衰期的adamts13-mdtcs融合蛋白及其应用
JP7007261B2 (ja) 2015-08-20 2022-01-24 アルブミディクス リミティド アルブミン変異体及びコンジュゲート
CA3183289A1 (en) 2015-09-08 2017-03-16 Jcr Pharmaceuticals Co., Ltd. Novel human serum albumin mutant
CN110498851B (zh) * 2015-11-10 2022-10-11 孙嘉琳 一种抗肿瘤蛋白内皮抑素的衍生物及应用
EP3387018A1 (en) 2015-12-11 2018-10-17 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
JP7146637B2 (ja) 2015-12-22 2022-10-04 アルブミディクス リミティド 改善されたタンパク質発現株
EP3394243A1 (en) 2015-12-22 2018-10-31 Albumedix Ltd. Improved protein expression strains
CN105646717B (zh) * 2016-01-26 2020-06-09 复旦大学 一种长效hiv融合抑制剂及其应用
US11130979B2 (en) 2017-06-20 2021-09-28 Albumedix Ltd Protein expression strains
WO2019032472A1 (en) * 2017-08-08 2019-02-14 The Board Of Trustees Of The Leland Stanford Junior University HIGH AFFINITY MODIFIED MATRIX INHIBITOR
SG11202001595SA (en) * 2017-08-31 2020-03-30 Singapore Health Serv Pte Ltd Angio-3 for treatment of retinal angiogenic diseases
JP7799945B2 (ja) 2017-09-22 2026-01-16 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック 変異型ウイルスタンパク質
WO2019060695A1 (en) * 2017-09-22 2019-03-28 Kite Pharma, Inc. CHIMERIC POLYPEPTIDES AND USES THEREOF
CN109879969B (zh) * 2017-12-06 2024-04-09 天士力生物医药股份有限公司 一种hm-3融合蛋白及其应用
CA3117961A1 (en) 2018-10-29 2020-05-07 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
DE102019000490A1 (de) * 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren
WO2020214638A1 (en) 2019-04-16 2020-10-22 Dyax Corp. Methods for quantitation of functional c1 esterase inhibitor (fc1-inh)
CN111995686B (zh) * 2019-05-27 2022-06-14 兰州大学 一种具有抗血管生成活性的药物及其制备方法
EP4090427A1 (en) 2020-01-13 2022-11-23 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
CN111494604B (zh) * 2020-05-11 2022-05-06 中国药科大学 蓝藻抗病毒蛋白n在制备抗炎药物中的应用
CN111560049B (zh) * 2020-05-17 2022-05-17 浙江大学 两性离子多肽及其衍生物以及以其为基础的纳米药物
WO2022007885A1 (zh) * 2020-07-08 2022-01-13 南京师范大学 融合多肽和多肽二聚体及其用途
US20250179209A1 (en) * 2022-03-09 2025-06-05 Immunofyx Anti-cancer n-terminal fc conjugated immunotherapeutics
AU2024247601A1 (en) * 2023-03-28 2025-10-23 Nb Health Laboratory Co., Ltd. Antibody, nucleic acid, cell and drug
EP4442251A1 (en) 2023-04-05 2024-10-09 Albumedix Ltd Formulations and uses thereof
AU2024353718A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Compositions for treating cancer
CN117924430B (zh) * 2024-03-22 2024-06-28 中国人民解放军军事科学院军事医学研究院 促进血小板生成的tpor结合肽

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US355547A (en) 1887-01-04 mebcee
CA91311A (en) 1904-11-15 1905-01-31 The Canadian Westinghouse Company, Limited Single phase alternating current motors
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8510219D0 (en) 1985-04-22 1985-05-30 Bass Plc Isolation of fermentation products
JPS6296086A (ja) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol 複合プラスミド
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8615701D0 (en) 1986-06-27 1986-08-06 Delta Biotechnology Ltd Stable gene integration vector
US4857467A (en) 1986-07-23 1989-08-15 Phillips Petroleum Company Carbon and energy source markers for transformation of strains of the genes Pichia
GB8620926D0 (en) 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
JP2873012B2 (ja) 1987-04-09 1999-03-24 デルタ バイオテクノロジー リミテッド 酵母ベクター
WO1989000103A1 (en) 1987-07-08 1989-01-12 Primtec Hold-pressure control and clamping in stacked multi-parting molding system having desynchronized injection periods
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
EP0387319B1 (en) 1988-07-23 1996-03-06 Delta Biotechnology Limited Secretory leader sequences
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5663143A (en) * 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
GB8924021D0 (en) 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5602307A (en) 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
DE4244915C2 (de) 1992-08-14 1998-12-03 Widmar Prof Dr Tanner DNA-Moleküle codierend Proteine, die an der O-Glykosylierung von Proteinen beteiligt sind
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US5464933A (en) * 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
WO1995021601A2 (en) * 1994-01-11 1995-08-17 Protein Engineering Corporation Kallikrein-inhibiting 'kunitz domain' proteins and analogues thereof
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE277081T1 (de) * 1994-01-11 2004-10-15 Dyax Corp Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
ATE355379T1 (de) * 1994-04-26 2006-03-15 Childrens Medical Center Angiostatin und verfahren zu seiner nutzung zur vermeidung der angiogenese
GB9411356D0 (en) 1994-06-07 1994-07-27 Delta Biotechnology Ltd Yeast strains
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6797488B1 (en) * 1997-12-08 2004-09-28 Beth Israel Deaconess Medical Center Methods of producing anti-angiogenic proteins
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US20030012792A1 (en) * 1998-05-22 2003-01-16 Holaday John W. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
US6087473A (en) 1999-05-26 2000-07-11 Zymogenetics, Inc. Kunitz domain polypeptide and materials and methods for making it
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
US20020048571A1 (en) * 1999-07-19 2002-04-25 Jeno Gyuris Chimeric polypeptides of serum albumin and uses related thereto
US20010056075A1 (en) * 1999-07-19 2001-12-27 Jeno Gyuris Chimeric polypeptides of serum albumin and uses related thereto
WO2001047958A2 (en) * 1999-12-29 2001-07-05 Zymogenetics, Inc. Kunitz domain polypeptide zkun10
WO2001074980A2 (en) 2000-04-03 2001-10-11 Novozymes A/S Enzyme tablets for cleaning improvement
US6946134B1 (en) * 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP2213743A1 (en) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
EP1197550A3 (en) * 2000-08-25 2002-11-20 Pfizer Products Inc. Methods and compositions for diagnosing and treating disorders involving angiogenesis
US20020159992A1 (en) * 2000-09-29 2002-10-31 Jack Henkin Antiangiogenic polypeptides and methods for inhibiting angiogenesis
AU2002364586A1 (en) * 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
GB0329722D0 (en) * 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
US9057061B2 (en) * 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique
GB0329681D0 (en) * 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
EP2556087A1 (en) * 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants

Similar Documents

Publication Publication Date Title
JP2005530484A5 (https=)
US10774124B2 (en) Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
JP2005538932A5 (https=)
ES2661310T3 (es) Proteínas mirac
JP4324325B2 (ja) 突然変異化il13−をベースとするキメラ分子
JPS6156197A (ja) リンホトキシンの細胞溶解活性を中和する抗体
JPH11240897A (ja) ウロキナーゼレセプター活性のペプチドインヒビター
JP2515928B2 (ja) 高分子量ヒト血管形成因子
JP2001518304A (ja) アンギオスタチン成分を含む融合タンパク質及び抗腫瘍療法におけるその使用
JP5208135B2 (ja) 組換え白血球阻害因子とヒルゲンのキメラタンパク質及びその薬物組成物
WO2002076486A2 (en) Histidine-rich glycoprotein
CN115028738A (zh) 一种Fc融合蛋白双重靶向降解剂及应用
WO2005095443A1 (ja) ペプチド改変を利用したドラッグデリバリーシステム
JP2005534330A5 (https=)
AU2013234365B2 (en) Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
JP2022501373A (ja) 改善された第viii因子長期半減期凝固複合体に関連する方法および組成物
AU2016216675A1 (en) Protease resistant mmutants of stromal cell derived factor-1 in the repair of tissue damage
HK1192845A (en) Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
HK1192845B (en) Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
HK1136211B (en) Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage
AU2002304352A1 (en) Histidine-rich glycoprotein